Stage IV Melanoma Completed Phase 2 Trials for Interferon alfa-2a, Recombinant (DB00034)

IndicationStatusPhase
DBCOND0028660 (Stage IV Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00026143Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant MelanomaTreatment